Cyramza (Ramucirumab)

~ Dr. Yang Liu

Ramucirumab (Cyramza) has gained 3 FDA improved indications since March 2015. Ramucirumab is a human vascular endothelial growth factor receptor 2 inhibitor which demonstrates effects on advanced gastric or gastro-esophageal junction adenocarcinoma after progression with platinum/5FU therapy, metastatic Non-small cell lung cancer with progression on or after platinum-based therapy or metastatic colorectal cancer after progression on prior therapies. This definitely shed light on the treatment of these three hard-to-manage cancers after initial therapy.

CLICK HERE to learn more about Cyramza (Ramucirumab).

CLICK HERE to view the FDA Approval Article.

CLICK HERE to learn more about Dr. Yang Liu, MD PhD.